\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Research Infrastructures Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment EIE Missions New European Bauhaus Horizon EuropeOn 15 April, the European Commission launched a feedback opportunity for Horizon Europe work programme 2025.
This survey gives you the opportunity to provide input for the development of the Horizon Europe ‘main’ work programme 2025.
The responses collected will contribute to the co-design exercise of the main work programme, covering all 6 clusters (Health; Culture, Creativity and Inclusive Society; Civil Security for Society; Digital, Industry and Space; Climate, Energy and Mobility; Food, Bioeconomy, Natural Resources, Agriculture and Environment), research infrastructures, European innovation ecosystems, the 5 EU Missions and the New European Bauhaus facility.
You can provide feedback for one or multiple sections / (sub)domains, according to what is most relevant to you.
Deadline to fill in the survey is 6 May 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
